Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
- PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
- The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP).
- Members of the advisory board include:
Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board. - Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL.